Long-term safety follow-up of people treated with ADP cell therapy for cancer
Tracks long-term safety of people who received ADP cell therapy for cancer.
Plain-language title generated from the registry record
Registry title: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Key facts
- Where
- Amsterdam, NetherlandsSee the site
- Phase
- Phase 1
Where in Netherlands
- Antoni van Leeuwenhoek ZiekenhuisAmsterdam, NetherlandsNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- USWM CT, LLC
- Trial code
- NCT03391778
- Record updated
- 11 August 2026
- Original description
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.Read full original descriptionShow less
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Inclusion: Participants who have received at least one dose of ADP adoptive cell therapy agent; Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it; Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy; Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; The investigator is responsible for review of medical history; Capable of giving signed informed consent.
Exclusion: None.